Newsletter Subject

The $1 Trillion Pill

From

angelpub.com

Email Address

newsletter@angelpub.com

Sent On

Thu, Feb 29, 2024 08:21 PM

Email Preheader Text

💊 Jason Stutman: Jason Stutman   The $1 Trillion Pill See this small, clear capsule? To y

💊 Jason Stutman: Jason Stutman   The $1 Trillion Pill See this small, clear capsule? [limitless pill capsule] It has the potential to enhance memory, prevent disease, and it could even add 20 years onto your life! It’s a truly unique substance that can also help you… - Learn a foreign language within months… - Become physically fitter… - Improve your sex life… - Increase your confidence levels… - Successfully treat mental health conditions, such as depression, PTSD, and addiction… - Conquer your fears and eliminate anxiety. It works so well that Elon Musk, Bill Gates, and Google co-founder Sergey Brin have all taken this pill… And Kevin O’Leary from Shark Tank invested $6 million in it! After all, it has the potential to $1 TRILLION by swiping market share from some of the most profitable disease treatments in the world, such as: - $35 billion on treatment for alcoholism… - $90 billion on PTSD… - $150 billion on depression… - $39 billion on smoking cessation… - $40 billion on treatments for neurodegenerative diseases… - $16.4 billion on diabetes treatments… - $2.1 billion on anorexia treatments… - And $635 billion on treatments for chronic pain. And this doesn’t even include the anti-aging drug market valued at $54 billion! But the best part is that this pill is on the brink of FDA approval… And early investors have the potential to make a FORTUNE in the process. In fact, I’ve pinpointed THREE stocks set to soar with its market debut. This is a stake in the future of your well-being and longevity… So don’t miss your chance to be part of this historic moment in medical innovation and make a legendary fortune in the process. [Discover the three stocks set to soar here.]( To your wealth, [jeff signature transparent] Jeff Siegel Investment Director, Green Chip Stocks P.S. A groundbreaking capsule that promises remarkable benefits ranging from memory enhancement and disease prevention, to potentially extending your life by 20 years is on the brink of FDA approval. Industry titans like Elon Musk, Bill Gates, and Sergey Brin have already shown interest because this pill could potentially disrupt markets worth billions of dollars. Early investors in three specific stocks have the opportunity to capitalize on this medical breakthrough. [Learn more about this breakthrough pill here.](  If you no longer wish to receive updates from The Back office you [may opt out here.]( The Back Office, Copyright © 2024, Angel Publishing, LLC., 3 E. Read Street, Baltimore, MD 21202. For customer service, please call [877-303-4529](tel:/8773034529). All rights reserved. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Angel Publishing and The Back Office does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law. Â

Marketing emails from angelpub.com

View More
Sent On

11/10/2024

Sent On

03/10/2024

Sent On

26/09/2024

Sent On

18/09/2024

Sent On

12/09/2024

Sent On

10/09/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.